Mahamaya board to meet on May 25 to consider FY26 results

0 min read     Updated on 20 May 2026, 08:51 PM
scanx
Reviewed by
Ashish TScanX News Team
AI Summary

Mahamaya Lifesciences Limited will hold a board meeting on May 25, 2026, to approve audited standalone and consolidated financial results for the year ended March 31, 2026. The trading window remains closed until 48 hours post-results declaration.

powered bylight_fuzz_icon
40836099

*this image is generated using AI for illustrative purposes only.

Mahamaya Lifesciences Limited has announced that its board of directors will meet on Monday, May 25, 2026. The primary agenda of the meeting is to consider and approve the company's financial performance for the fiscal year ending March 31, 2026.

Agenda for the Meeting

The board will deliberate on the audited standalone financial results for the half year and financial year ended March 31, 2026, along with the accompanying audit report. Additionally, the directors will consider the audited consolidated financial results for the same periods.

Trading Window Closure

In continuation of a previous intimation dated March 30, 2026, regarding the closure of the trading window, the company stated that the window will remain shut. The closure is effective until 48 hours after the declaration of the financial results, in accordance with the company's Insider Trading Code and the SEBI (Prohibition of Insider Trading) Regulations, 2015.

The meeting is scheduled to be held at the company's registered office located in Gurugram, Haryana.

Historical Stock Returns for Mahamaya Lifesciences

1 Day5 Days1 Month6 Months1 Year5 Years
+0.58%-2.20%-0.46%+48.05%+49.14%+49.14%

How might Mahamaya Lifesciences' FY2026 financial results compare to industry peers in the life sciences sector, and what growth trajectory could investors expect going forward?

Following the board meeting on May 25, 2026, will the company announce any dividend declarations, capital expenditure plans, or strategic expansions that could impact its stock performance?

How could the reopening of the trading window after the results announcement influence institutional and retail investor sentiment toward Mahamaya Lifesciences stock?

like17
dislike

Mahamaya Lifesciences Limited Exempt from Corporate Governance Compliance Due to BSE SME Listing

1 min read     Updated on 15 Apr 2026, 07:51 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Mahamaya Lifesciences Limited has notified BSE Limited about its exemption from corporate governance compliance requirements under SEBI regulations. The company's listing on the BSE SME platform qualifies it for exemption under Regulation 15(2)(b), relieving it from filing quarterly, half-yearly, and yearly corporate governance reports as required under Regulation 27(2) of SEBI (LODR) Regulations, 2015.

powered bylight_fuzz_icon
37808471

*this image is generated using AI for illustrative purposes only.

Mahamaya Lifesciences Limited has officially informed BSE Limited about its exemption from corporate governance compliance requirements under SEBI regulations. The company submitted a formal communication dated April 15, 2026, to BSE's Listing Compliance Department regarding this regulatory exemption.

Regulatory Exemption Details

The company has invoked the non-applicability criteria provided under Regulation 15(2)(b) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This exemption is specifically available to companies whose equity shares are listed on the BSE SME Platform.

Exemption Parameter: Details
Applicable Regulation: SEBI (LODR) Regulations, 2015
Exemption Clause: Regulation 15(2)(b)
Listing Platform: BSE SME Platform
Exempted Requirement: Corporate Governance Reports

Impact on Compliance Requirements

Due to this exemption, Mahamaya Lifesciences Limited is not required to file corporate governance reports as mandated under Regulation 27(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The exemption covers:

  • Quarterly corporate governance reports
  • Half-yearly corporate governance reports
  • Yearly corporate governance reports

Company Information

Mahamaya Lifesciences Limited, formerly known as Mahamaya Lifesciences Pvt. Ltd., operates from its registered office located at Spaze ITech Park, Sector-49, Sohna Road, Gurugram, Haryana. The company holds CIN L24233DL2002PLC115261 and maintains ISO 9001:2015 certification.

Official Communication

The formal notification was signed by Shilpi Bhardwaj, Company Secretary & Compliance Officer (Membership No.: A24444), and submitted to BSE Limited for official records. The communication ensures transparency regarding the company's compliance status under current SEBI regulations for SME-listed entities.

Historical Stock Returns for Mahamaya Lifesciences

1 Day5 Days1 Month6 Months1 Year5 Years
+0.58%-2.20%-0.46%+48.05%+49.14%+49.14%

Will Mahamaya Lifesciences consider graduating to the main board listing in the future, which would require full corporate governance compliance?

How might this exemption from governance reporting requirements affect investor confidence and institutional investment interest?

Could SEBI potentially revise the corporate governance exemption criteria for SME platform companies in upcoming regulatory updates?

like18
dislike

More News on Mahamaya Lifesciences

1 Year Returns:+49.14%